Bone Marrow Transplantation
Leung et al 1 recently reported their results in 22 infants with acute leukemia or myelodysplasia who underwent allogeneic BMT. Patients received a radiation-containing regimen prior to BMT. The authors report a 5-year eventfree survival of 45.5%.
Total body irradiation had been recognized to be associated with adverse effects on the growth and endrocrinologic status of BMT recipients. In a study concerning late effects of treatment in survivors of childhood AML, Leung et al 2 reported that younger age (at the time of diagnosis or initiation of radiation therapy) was a risk factor for development of academic difficulties and greater decrease in height. Furthermore, they concluded that those who received TBI and allogeneic BMT had an increased risk for development of growth hormone deficiency, hypothyroidism, hypogonadism, infertility and cataracts. Similarly, Cohen et al 3 concluded in their study of final height of patients who had undergone BMT during childhood that irradiation was one of the major factors for long-term height loss.
Regimens containing no radiation for conditioning of infants with acute leukemia prior to BMT have been reported to result in satisfactory outcomes. Marco et al 4 reported a 5-year disease free survival of 63% in 26 patients with infantile leukemia after BMT (eight allogeneic and 18 autologous), only one patient received TBI, the remainder received conditioning with chemotherapy only. Infants who had AML fared better than those with ALL (73% vs 56%, respectively, although P was not significant). On the other hand, our results have not been as rewarding at King Faisal Specialist hospital. Using chemotherapy only as conditioning prior to BMT, 12 infants with acute leukemia underwent allogeneic BMT between October 1993 and March 2001, five had acute lymphoblastic leukemia and seven had acute myeloid leukemia. The median age at BMT was 15.25 months (range, 9.5-23.5 months). All patients were in remission before BMT. All donors were HLAidentical (nine from siblings and three from a parent). Harvested bone marrows were not manipulated, the median CD34-positive cell count was 8 ϫ 10 6 /kg of recipient body weight (range, 0.63-15.4). The conditioning regimen in 11 patients consisted of busulphan (BU) at total dose of 12 mg/kg, cyclophosphamide (CY) at a total dose of 120 mg/kg, and etoposide at a total dose of 60 mg/kg. One patient received BU/CY only. At 45 months post-BMT, our event-free survival was 25%. When analyzed separately, however, the event-free survival for patients with AML was 45%. All patients with ALL died (three had relapse of their disease, one died of severe acute GVHD of the gut, and one died of pulmonary fibrosis).
When compared with our results, Leung's data suggest that the use of TBI may offer better results. We believe, however, that its role in the conditioning of infants undergoing BMT is still not clearly defined. Further multiinstitutional randomized studies are required to clarify this controversial issue.
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Ayas et al pointed out the important controversy concerning the optimal conditioning regimen for infants with leukemia, a controversy that also exists for the older pediatric population. 1, 2 Because the risk of late sequelae after TBI and BMT is inversely proportional to age, 3, 4 attempts have been made to delay transplantation until the patient is older or to eliminate TBI from the conditioning regimen. 5 These approaches are advised, provided that survival is not compromised. 6 The study by Marco et al 7 has demonstrated that transplantation within 4 months after complete remission is achieved may be associated with a better prognosis than transplantation performed after 4 months. Data from some studies suggest that patients with acute myeloid or acute lymphoblastic leukemia have a better survival rate when they are treated with TBI-containing matched-sibling BMT than with non-TBI-containing transplantation. 1, 8 Although multi-institutional randomized studies are ideal to address the controversy concerning conditioning for infants with leukemia, the number of infants with this rare, biologically heterogeneic disease is limited. While the controversy about the optimal conditioning regimen is likely to remain in the near future, its importance may be diminished with the development of more effective post-transplantation therapy, such as immunotherapy for infections and minimal residual disease. A 59-year-old male patient with myelofibrosis was referred for allogeneic stem cell transplantation. Three years prior to the referral (March 1996), the patient was diagnosed with myelofibrosis by bone marrow biopsy. At that time he had pancytopenia and 6-10 cm splenomegaly. He was initially treated with interferon but this was discontinued after 8 weeks due to falling blood counts. The patient was then begun on RBC transfusions. His initial antibody screen was negative (July 1996) . In August 1996, the patient was noted to have a weak cold agglutinin and positive direct antiglobulin test. The direct antiglobulin test was positive for both IgG and C3 with a nonspecific eluate. Over the next 24 months, the patient received a total of 24 units of packed RBCs. In August 1998, an antibody screen revealed the presence of anti-C, Kell (K), and the weak cold agglutinin. Repeat antibody screen after several additional transfusions showed anti-C, E, K, and the weak cold agglutinin. In October 1998, a further antibody screen demonstrated an additional anti-Kpb. Red cell phenotype revealed that the patient was negative for C, E, K, Kpb. From October 1998 until December 1999, the patient did not receive any red cell transfusions due to concerns about alloantibodies. He did receive several courses of methylprednisolone that decreased his transfusion requirements but did not raise the patient's hemoglobin above 8 g/dl. During this time, antibodies to C, E, Kpb, K continued to be positive (2+). In January 2000, due to progressive disease, the patient was begun on Rituximab 375 mg/m 2 i.v. once weekly for 4 weeks in an effort to clear the alloantibodies. Five weeks later, the patient was found to have no evidence of antibodies or cold agglutinins by direct and indirect antiglobulin tests. In February 2000, the patient underwent umbilical cord blood transplantation. Due to significant GI bleeding, the patient received 70 units of packed RBCs after the transplant. All red blood cell units were positive for one or more of the previously noted antigens. The patient expired
